medication-assistedtreatment 101
MAT Symposium
medication overview & a review of theevidence
Adrienne C. Lindsey, MA, DBHAugust 2014
Part 1
the neuroscience ofaddiction
overview of addictionand the brain
substancesaffect thebrain
chemically
structurally
behaviorally
the reward pathwaydrugs & alcohol acton the rewardpathway, the sameregion activated by:
• eating• sex• drinking• other pleasurable
activities
chemical changes
the role of dopamine• increase in available dopamine
• results in pleasurable feelings
• the behavior is reinforced
• the effect of previouslypleasurable activities is blunted
non-druguser
heavycocaine
user
(National Institute on Drug Abuse, 2010)
smoker
non-smoker
alcoholic
normal normal normal
obese cocaine
(Volkow, 2001)
healthy brain
healthy heart diseased heart
diseased brain/cocaine abuser
Decreased Brain Metabolism in Drug Abuser
Decreased Heart Metabolism inHeart Disease Patient
(National Institute on Drug Abuse, 2010)
glutamate
endogenousopioids
GABA
serotonin
structural changes
(National Institute on Alcohol Abuse & Alcoholism, 2004)
healthyelderlyperson
person withAlzheimer’s
disease
heavydrinker
alcoholicbrain
controlbrain
Oscar-Berman, M., Valmas, M., Sawyer, K.S., Ruiz, S.M., Luhar, R., & Gravitz, Z. (2014). Profiles of impaired, spared, andrecovered neuropsychological processes in alcoholism. In Pfefferbaum, A. & Sullivan, E.V. (Eds.), Handbook of ClinicalNeurology: Alcohol and the Nervous System. Edinburgh: Elsevier (in press).
(National Institute on Alcohol Abuse & Alcoholism, 2004)
control brain alcoholic brain
behavioral changes
classical and operant conditioning
behaviorsthat are
rewardedare likely
to berepeated
positive reinforcement
negative reinforcement
environmental cues
recovery
healthy brain
cocaine abuser (10 days clean)
cocaine abuser (100 days clean)
(National Institute on Drug Abuse, 2007)
leve
l of b
rain
act
ivity
(low
to h
igh)
normal control meth abuser(1 month ofabstinence)
meth abuser(14 months ofabstinence)
(National Institute on Drug Abuse, 2002)
review: substancesaffect the brain…
chemically
structurally
behaviorally
mythbustingPart 2
the facts and fictionof medication-assisted treatment
“…treatment for a substance use
disorder that includes a
pharmacological intervention as part
of a comprehensive substance abuse
treatment plan...”
how MATworks
easeswithdrawal
reducescravings
inducesillness
myth #1: MAT isjust replacing onedrug with another.
MAT vs. illicit drugsprescribed/monitoredby a medical provider
FDA-approved
regulated potency
curbs cravings andwithdrawal symptoms
obtained by illegalmeans
not legally permitted
potency varies
results in euphoriaor a “high”
myth #2: MATdoesn’t work.
to beapproved bythe FDA,medicationsmust beshown to besafe, but alsoeffective
treatmentoutcomes forbuprenorphine(Suboxone)
increasedtreatmentretention
decrease inself-reportedcravings
decreasedillicit opioiduse
treatmentoutcomes formethadone
increased treatmentretention
decreased illicit opioiduse
8-10 fold decrease indrug-related deaths
increase inemployment rates
decrease in criminalactivities
treatmentoutcomesfor alcoholmedications
reduces total numberof drinking days
reduces number ofheavy drinking days
increased likelihoodfor abstinence;reduces the risk ofrelapse
reductions in criminalrecidivism
myth #3: If someoneis clean, they don’tneed MAT.
drug overdose is one ofthe leading causes ofdeath for individualsbeing released from
prison or jail
Reductions in Mortality
Drug overdose was the leading cause of death for
those released from Washington State prisons
between 1999 and 2003 (Binswanger et al., 2007).
Before…
Homicides,
Suicides,
Heart disease, and…
Motor vehicle accidents
myth #4: MAT isn’tsupported by 12-Stepprograms.
“No A.A. member should ‘playdoctor;’ all medical advice andtreatment should come from aqualified physician.”
--A.A. General Service Office(Member Medications & Other Drugs brochure)
“…just as it is wrong to enable orsupport any alcoholic to becomereaddicted to any drug, it’s equallywrong to deprive any alcoholic ofmedication, which can alleviate orcontrol other disabling physicaland/or emotional problems.”
--A.A. General Service Office(Member Medications & Other Drugs brochure)
“NA as a whole has no opinion on outsideissues, including prescribed medications.Use of psychiatric medication and othermedically indicated drugs prescribed bya physician and takenunder medicalsupervision isnot seen ascompromising aperson’s recovery inNA.”
myth #5: MAT is tooexpensive
many MAT medicationscan be found onstate Medicaid/Medicareformularies
RBHAformulary
buprenorphine/naloxone
buprenorphine
disulfiram
acamprosate
naltrexone
for thosepatients whodo not qualifyfor Medicaid or Medicaremany patient assistanceprograms are availablethrough the drugmanufacturers
grant funding
private insurance
prescription discountcards
tribal funds
additional MAT funding sources
Part 3
the medicationsuses and considerations
medicationsfor alcohol
naltrexone
acamprosate
disulfiram
mechanism: blocks the pleasurableeffects of alcohol; reduces alcoholcravings
pros can be used for alcohol & opioiddependence, non-addictive,reduces drinking episodes& volume, extended releaseavailablecons non-compliance
naltrexone (Depade®, ReVia®, Vivitrol®)
mechanism: assists in post-acutewithdrawal symptoms (e.g. irritability,anxiety, agitation)
pros non-addictive, can assist patient inmaintaining abstinence,not easily abused/misused, affordablecons patient must beabstinent to begintreatment
acamprosate (Campral®)
mechanism: makes patient physicallyill when ingesting alcohol
pros non-addictive, affordable ($60/mos),useful with chronic alcoholismcons non-compliance,risk of death for thosewith existing healthconditions, may not beappropriate for SMI px’s
disulfiram (Antabuse®)
medicationsfor opioids
methadone
buprenorphine
naltrexone
how do opioidswork?
dose of opioid
opioideffect
full agonist(e.g.,methadone)
(e.g. naloxone)antagonist
partial agonist(e.g. buprenorphine)
mechanism: full agonist (acts on opioidreceptors), alleviates withdrawalsymptoms & cravings
pros affordable (usually gov’t subsidized),convenient dosing (1x/day), demonstratedsafety for pregnant womencons intoxicationwith too high a dose,risk of overdose
methadone (Methadose®, Dolophine®)
mechanism: partial agonist - blockseuphoric effects of opioids, alleviateswithdrawal, assists with cravings
pros easier to taper than methadone,less risk of OD than methadone,available in a sublingualfilm, naloxonediscourages abusecons costly $$$
buprenorphine (Subutex®)buprenorphine/naloxone (Suboxone®)
new FDA-approved buprenorphine/naloxone generic sublingual film
expected release: Oct. 2014
manufacturer claims 2xthe bioavailability
-allows for lower dose(arguably less risk forabuse)
buprenorphine/naloxone (Bunavail®)
injectable buprenorphine; once amonth dosing
buprenorphine implant,good for 6 months
more to come….
upcoming products
mechanism: full antagonist (blocksopioid receptors)
pros prevents euphoric effects ofopioids; non-addictive;extended releaseavailable
consnon-compliance
naltrexone (Depade®, ReVia®, Vivitrol®)
building a case for MATPart 4
a review of the evidenceand patient benefits
substance abusetreatment is effective andcost-neutral…
…but half ofconsumers will
be lost toattrition
improved treatment retention
improvedfunctioning
lower risk ofoverdose
reduced criminal activity
reducedsubstance use
employment
benefits of MAT
improved treatmentretention
counselingonly
23 days incommunity treatment
0offenders remained in
treatment at 1 year
counseling +methadone
166 days in communitytreatment
1/3of offenders remained in
treatment at 1 year
(Kinlock, Gordon, Schwartz, Fitzgerald & Grady, 2009)
n=204; randomly assigned
reductions insubstance use
204prison inmates received counseling or counseling and
methadone treatment services (Kinlock et al., 2009)
2xas many inmates in the counseling only group
screened positive for opioids at 1 year post-release
interim methadone treatment
(Schwartz, Jaffe, Grady, Das, Highfield, & Wilson, 2009)
762patients
24buprenorphine clinical trials
4,500opioid-addicted patients
buprenorphinewas significantlymore effective at reducingillicit opiate usethan placebo
(Mattick, Kimber, Breen & Davoli, 2008)
naltrexone v placebo
fewer slips
fewer significant relapses
fewer total drinking days
(O’Brien, Volpicelli, &Volpicelli, 1996)
naltrexone vplacebo
reduced consumption
fewer relapses
cont’d abstinence
(O’Malley et al., 1992)
reduced mortality
8-10fold reduction in deaths for opiate dependent individuals usingmethadone
13xhigher mortality rate for opiate users than non opiate users
death rates in treated &untreated heroin addicts
MAT has also beenfound to reduce…
risky behaviors-IV drug use-unprotected sex
reducing…-HIV-Hepatitis C
reductions incriminal activity
MAT can reducecriminal activity
and reincarceration
Reductions in Recidivism
annu
al c
rime
days
Annual Crime Days Before Methadone Treatment and During MethadoneTreatment (amongst 6 programs) (Ball & Ross, 1991)
Reductions in Recidivism
• 342 inmates with opioiddependence
• methadone maintenance whileincarcerated; referral formethadone clinic upon release
• reincarceration rates werereduced by 70% whileparticipants were enrolled intreatment(Dolan et al., 2004)
Reductions in Arrests
• 300+ opiate dependent clients
• interim methadone treatmentvs. no treatment/waiting list
• significantly fewerarrests at 6 months(Schwartz, Jaffe, O’Grady,Kinlock, Gordon, Kelly,Wilson & Ahmed, 2009)
improvements inemployment status
↑ functioning↑ employment outcomes
cost savings
$27,802average annual cost per offender for incarceration in
Pima County jail
$11,442average cost per offender for one year of out-of-
pocket MAT services and standard probation
$7,354if an offender pays 40% of his or her treatment costs, the cost of
one year of standard probation and MAT services drops to
$16,360annual savings per year, per offender, when providing MAT servicesto an offender on community supervision, as opposed to incarceratingthat individual for one year
$72.5 billionannual healthcare costs related to prescription opioid misuse/abuse
MAT cost-savings
improved healthoutcomes
improvedproductivity/reducedabsenteeism &presenteeism
reduced criminalactivity
reducedrecidivism/reincarceration
MAT referralprocess simplified
Part 5
identifying appropriate candidatesand locating providers
identifying MATcandidates
appropriate MATcandidates
history of use
previous failedtreatmentattempts
openness to tryMAT
activepsychosis
serioushealthconditions
dependenton multiplesubstancesinappropriate
MAT candidates
medical professionals will makethe ultimate determinationaround eligibility…
locating an MATprovider
The Substance Abuse and Mental Health ServicesAdministration’s buprenorphine physician locator canidentify those providers in your area who are certifiedto prescribe buprenorphine
buprenorphine.samhsa.gov
the Single-State Agency (SSA) for substance abusetreatment providers for your state can point you to MATproviders in your area…
other MAT providerresourcesin-house treatmentcoordinators/liaisons
existing contractedproviders
requesting MAT ofexisting providers
help us help you…-name of agency-contact info.-forms of MAT-forms ofpayment
OR…
names of providersyou’re referring to
funding MAT
financing
Medicare/Medicaid
private insurance
patient-assistanceprograms
prescriptiondiscount cards
grant funding
tribal funds
changes in agerestrictions
substance abusetreatment parity
health exchanges
employermandates
Medicaid expansion
healthcare reformimplications
strengtheningrelationships with
MAT providers
strengtheningrelationships
cross-trainings
liaisons
contractualarrangements